CABA - Cabaletta Bio, Inc.

QQQ $ 629.16 $ 3.02 (0.48 %)

DIA $ 475.58 $ 0.66 (0.14 %)

SPY $ 681.80 $ 2.23 (0.33 %)

TLT $ 90.21 $ -0.27 (-0.3 %)

GLD $ 368.20 $ -2.01 (-0.54 %)

Previous Close

$ 3.61

Open

$ 2.61

Bid

$ 3.47 x 820

Ask

$ 3.57 x 10

Day's Range

$ 2.56 - $ 3.67

52 Week Range

$ 0.99 - $ 5.46

Volume

35,910,240

Average Volume

Market Cap

330.19M

Beta (5Y Monthly)

$ 2.73

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-15-2024	03-31-2024	10-Q
7	03-21-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-16-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-17-2022	12-31-2021	10-K
16	11-01-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-03-2021	03-31-2021	10-Q
19	03-16-2021	12-31-2020	10-K
20	11-10-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-12-2020	03-31-2020	10-Q
23	03-30-2020	12-31-2019	10-K
24	12-05-2019	09-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Friday's I...
10/31/2025 17:06:11

Cantor Fitzgerald Maintains Overweight on ...
10/31/2025 13:43:36

Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target ...

Cabaletta Bio Announces Clinical Data And ...
10/27/2025 11:10:47

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria...

HC Wainwright & Co. Reiterates Buy on Caba...
10/10/2025 10:43:12

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.

$cabaletta-bio-reports-initial-results-for-rese-cel-in-pemphigus-vulgaris-without-preconditioning-shows-complete-b-cell-depletion-rapid-reduction-in-autoantibodies-and-near-complete-resolution-of-clinical-symptoms-in-two-of-three-refractory-patients$

Cabaletta Bio Reports Initial Results For ...
10/09/2025 16:11:59

– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of thre...

Cantor Fitzgerald Reiterates Overweight on...
09/05/2025 13:47:43

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price tar...

vinay-prasads-comeback-to-fda-sparks-debate-over-regulatory-direction

Vinay Prasad's Comeback To FDA Sparks Deba...
08/11/2025 12:45:28

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vac...

Wells Fargo Maintains Equal-Weight on Caba...
08/08/2025 15:05:34

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from...

Cabaletta Bio Q2 EPS $(0.73) Misses $(0.61...
08/07/2025 11:57:24

whats-going-on-with-sarepta-capricor-and-other-gene-therapy-stocks-on-wednesday

What's Going On With Sarepta, Capricor And...
07/30/2025 15:07:26

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controve...

12 Health Care Stocks Moving In Wednesday'...
07/23/2025 21:05:58

fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers

FDA Eases Access To Life-Saving Gene Thera...
06/30/2025 12:36:39

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and a...

12 Health Care Stocks Moving In Wednesday'...
06/11/2025 17:06:34

HC Wainwright & Co. Reiterates Buy on Caba...
06/11/2025 16:56:57

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $25 price target.

Cabaletta Bio Prices $100M Public Offering...
06/11/2025 13:56:01

Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focuse...

Cabaletta Bio Earlier Announced Proposed P...
06/11/2025 13:12:37

Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focuse...

12 Health Care Stocks Moving In Wednesday'...
06/11/2025 12:07:40

Cabaletta Bio Reveals That New Rese-cel Sa...
06/11/2025 10:02:05

Citigroup Maintains Buy on Cabaletta Bio, ...
05/16/2025 15:17:34

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $17 to...

Guggenheim Maintains Buy on Cabaletta Bio,...
05/16/2025 15:16:34

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $23 to $25.